Maxcyte, Inc. (MXCT): who owns it and who trades it
As of Nov 16, 2026, MXCT insiders reported 1 open-market sale worth $8.3K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Douglas J Swirsky (CFO), with $8.3K. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Maxcyte
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns MXCT
124 funds and institutions reported MXCT shares worth $78.2M at the end of Q2 2026, about 59% of the company. The largest holder is Capricorn Fund Managers Ltd with 7.7%.
Funds and institutions (13F) 59%Everyone else 41%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8.20M | 7.67% | $10.1M | No change |
| Vitruvian Partners LLP | 5.04M | 4.72% | $6.2M | No change |
| Vanguard Capital Management LLC | 4.03M | 3.77% | $5M | +1% |
| Morgan Stanley | 3.69M | 3.46% | $4.5M | +0% |
| Mudita Advisors LLP | 3.37M | 3.15% | $4.1M | No change |
| BlackRock, Inc. | 3.06M | 2.86% | $3.8M | -65% |
| Brooklands Fund Management Ltd | 2.85M | 2.67% | $3.7M | +30% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2.77M | 2.60% | $3.4M | No change |
| Cadian Capital Management, LP | 2.20M | 2.06% | $2.7M | +28% |
| Peapod Lane Capital LLC | 2.13M | 1.99% | $2.6M | +60% |
| Renaissance Technologies LLC | 1.91M | 1.79% | $2.4M | -4% |
| AQR Capital Management LLC | 1.88M | 1.76% | $2.3M | +54% |
| Jane Street Group, LLC | 1.56M | 1.46% | $1.9M | +7499% |
| Two Sigma Investments, LP | 1.46M | 1.37% | $1.8M | +141% |
| Geode Capital Management, LLC | 1.33M | 1.24% | $1.6M | -44% |
| RBF Capital, LLC | 1.32M | 1.24% | $1.6M | – |
| Goldman Sachs Group Inc | 1.24M | 1.16% | $1.5M | +7% |
| Millennium Management LLC | 1.20M | 1.13% | $1.5M | +2698% |
| Nano Cap New Millennium Growth Fund L P | 1.20M | 1.12% | $1.5M | +20% |
| Marshall Wace, LLP | 1.01M | 0.95% | $1.2M | +926% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, MXCT insiders reported $0 of open-market purchases and $8.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | Douglas J Swirsky | CFO | Sale | 10,142 | $0.82 | $8.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Douglas J Swirsky | CHIEF FINANCIAL OFFICER | – | $8.3K | Mar 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
MXCT short interest
Low short interest. 1.5% of MXCT shares are sold short: about 1 share in 65. Over the last 12 reports the number of shares short went down 66%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.58M MXCT shares were sold short, 1.5% of the shares outstanding, down 13.6% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 1.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.58M | 1.53% | -14% | 1.18M | 1.3 |
| Oct 15, 2026 | 1.83M | 1.77% | +68% | 1.71M | 1.1 |
| Sep 30, 2026 | 1.09M | 1.06% | -7% | 346,888 | 3.1 |
| Sep 15, 2026 | 1.17M | 1.13% | -10% | 417,192 | 2.8 |
| Aug 31, 2026 | 1.30M | 1.26% | +6% | 548,574 | 2.4 |
| Aug 14, 2026 | 1.23M | 1.19% | -1% | 1.09M | 1.1 |
| Jul 31, 2026 | 1.24M | 1.16% | -12% | 784,404 | 1.6 |
| Jul 15, 2026 | 1.41M | 1.32% | -7% | 1.15M | 1.2 |
| Jun 30, 2026 | 1.52M | 1.42% | -64% | 2.36M | 1.0 |
| Jun 15, 2026 | 4.24M | 3.97% | -5% | 734,485 | 5.8 |
| May 29, 2026 | 4.47M | 4.18% | -5% | 1.18M | 3.8 |
| May 15, 2026 | 4.72M | 4.42% | -10% | 1.25M | 3.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Maxcyte company events
Maxcyte filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership, listing). The latest was on Nov 10, 2026.
- Nov 10, 2026AgreementMaxCyte, Inc. entered into a Securities Purchase Agreement with Ohio TopCo LP and Arcline Capital Partners A LP (together, the “ Sellers ”), affiliates of Arcline Investment Management, and the other parties thereto, pursuant to which the Company will acquire, indirectly, all of the outstanding… Filing
- Oct 14, 2026ResultsReleased financial results. Filing
- Aug 12, 2026ResultsReleased financial results. Filing
- Jun 17, 2026VoteReported shareholder vote results. Filing
- Jun 16, 2026ListingAs previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, because the closing bid price for the Company’s… Filing
- May 12, 2026ResultsReleased financial results. Filing
- Mar 27, 2026LeadershipThe Board of Directors of MaxCyte, Inc. appointed Parmeet Ahuja as the Company’s Chief Financial Officer, effective March 30, 2026. Filing
- Mar 24, 2026ResultsReleased financial results. Filing
- Mar 20, 2026ListingMaxCyte, Inc. received notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive trading days, the Company no longer complies with the minimum bid price… Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Maxcyte financials
Famous investors that hold MXCT
5 of the 50 well-known investors we track reported holding MXCT in their latest 13F filing. The largest position is Jim Simons's, worth $2.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 2.04M | $2.3M | 0.0% | +7% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.15M | $1.3M | 0.0% | +34% |
| Israel Englander · Millennium Management | Q3 2026 | 689,847 | $773K | 0.0% | -43% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 68,473 | $76.7K | 0.0% | -77% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 62,075 | $69.5K | 0.0% | -21% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named MXCT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 2, 2026 | Liontrust Investment Partners LLP | 13D | 4.9% |
| Nov 2, 2026 | Liontrust Investment Partners LLP | 13D | 4.9% |
| Oct 15, 2026 | Liontrust Investment Partners LLP | 13D | 5.0% |
| Oct 15, 2026 | Liontrust Investment Partners LLP | 13D | 5.0% |
Questions about Maxcyte, Inc. (MXCT) stock
Who owns the most MXCT stock?
The largest reported owner of Maxcyte, Inc. (MXCT) is Capricorn Fund Managers Ltd, with 7.7% of the company. In total, 124 funds and institutions reported holding MXCT at the end of Q2 2026, together about 59% of the shares. See the largest owners.
Are MXCT insiders buying or selling?
In the last 12 months, MXCT insiders reported no open-market purchases and 1 sale worth $8.3K. The latest trade was on Mar 17, 2026. See every trade.
What is the short interest in MXCT?
As of Oct 30, 2026, 1.58M MXCT shares were sold short, 1.5% of the shares outstanding, down 13.6% from the report before. At the average daily volume of 1.18M shares, buying them all back would take about 1.3 trading days (days to cover). See the history.
Which famous investors hold MXCT?
5 of the 50 well-known investors we track reported MXCT in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $2.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.